Moderate To Severe Chronic Obstructive Pulmonary Disease clinical trials

Explore recruiting moderate to severe chronic obstructive pulmonary disease clinical trials.

Recruiting moderate to severe chronic obstructive pulmonary disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Chronic Obstructive Pulmonary Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Denmark, Sweden, Poland, Estonia, Portugal, Latvia +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Germany, Romania, Greece, Norway, Netherlands, Poland +4 more

Phase II and Phase III (Integrated) EU CTIS Study details

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Spain, Germany, Poland, Czechia, Greece, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease

Hungary, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Romania, Lithuania, Hungary, Spain, Bulgaria, Ireland +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER 01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

Bulgaria, Poland, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Moderate To Severe Chronic Obstructive Pulmonary Disease trials by city

Moderate To Severe Chronic Obstructive Pulmonary Disease in Toronto Moderate To Severe Chronic Obstructive Pulmonary Disease in Vancouver Moderate To Severe Chronic Obstructive Pulmonary Disease in Montreal Moderate To Severe Chronic Obstructive Pulmonary Disease in Calgary Moderate To Severe Chronic Obstructive Pulmonary Disease in Edmonton Moderate To Severe Chronic Obstructive Pulmonary Disease in Ottawa Moderate To Severe Chronic Obstructive Pulmonary Disease in Winnipeg Moderate To Severe Chronic Obstructive Pulmonary Disease in Quebec City Moderate To Severe Chronic Obstructive Pulmonary Disease in Hamilton Moderate To Severe Chronic Obstructive Pulmonary Disease in Kitchener Moderate To Severe Chronic Obstructive Pulmonary Disease in London Moderate To Severe Chronic Obstructive Pulmonary Disease in Halifax Moderate To Severe Chronic Obstructive Pulmonary Disease in New York Moderate To Severe Chronic Obstructive Pulmonary Disease in Los Angeles Moderate To Severe Chronic Obstructive Pulmonary Disease in Chicago Moderate To Severe Chronic Obstructive Pulmonary Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease